Vertex and Tibotec have provided additional data to these authorities, including the results to be disclosed at AASLD
Tibotec is pleased to present the final results of the phase 2b PILLAR study at AASLD
1) A Randomized, Double-blind, Placebo Controlled Safety and Anti-viral Proof of Concept Study of Miravirsen, an Oligonucleotide Targeting miR-122, In Treatment Naive Patients with Genotype 1 Chronic HCV Infection, Abstract AASLD
Please note that Medivir will be hosting meetings for Investors, Analysts and the Media at the AASLD
(see end of press release).
The data to be reported at the AASLD
meeting are the results of a Phase 1a dose-ranging trial of PPI-461 in healthy volunteers completed this year.
Additionally, recent telaprevir data from studies led by Vertex were also presented at AASLD
, including the final results of the PROVE 2 study.
Accepted titles for Abstracts to be presented at the 2010 AASLD
meeting are as follows:
The data presented at AASLD
included safety and efficacy results for the first 1,354 patients retreated in the study.
The final results presented at AASLD
included patients who received the higher doses of R1626 at 3,000 mg or 4,500 mg twice a day.
The full abstract can be viewed at the AASLD
website at www.
Antiviral Activity of SCH 503034, a HCV Protease Inhibitor, Administered as Monotherapy in Hepatitis C Genotype-1 (HCV-1) Patients Refractory to Pegylated Interferon (Peg-IFN-a), Abstract 67484, AASLD
The C208 presentation at AASLD
will include SVR data (defined as undetectable HCV RNA at 24 weeks after completion of treatment) and represents the first SVR data for telaprevir-based regimens as part of a response-guided therapy trial design, similar to that being used in the Phase 3 trials of telaprevir.